Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases

A crossover study was planned in order to compare the effects of captopril and slow channel calcium entry blocker (Ca antagonist) on urinary protein excretion in 7 hypertensive patients with renal diseases, including 4 with IgA nephropathy, 2 with lupus nephritis and 1 with benign nephrosclerosis. C...

Full description

Saved in:
Bibliographic Details
Published inNephron (2015) Vol. 52; no. 1; p. 72
Main Authors Ikeda, T, Nakayama, D, Gomi, T, Sakurai, J, Yamazaki, T, Yuhara, M
Format Journal Article
LanguageEnglish
Published Switzerland 1989
Subjects
Adult
Calcium Channel Blockers - therapeutic use
Captopril - therapeutic use
Clinical Trials as Topic
Female
Humans
Hypertension, Renal - drug therapy
Male
Middle Aged
Proteinuria - drug therapy
Online AccessGet more information

Cover

More Information
Summary:A crossover study was planned in order to compare the effects of captopril and slow channel calcium entry blocker (Ca antagonist) on urinary protein excretion in 7 hypertensive patients with renal diseases, including 4 with IgA nephropathy, 2 with lupus nephritis and 1 with benign nephrosclerosis. Captopril decreased urinary protein excretion by 52% without any change in creatinine clearance, while Ca antagonist was having a slight effect on proteinuria even though the drug showed an equivalent antihypertensive effect as captopril. These results suggest that the attenuation of proteinuria induced by captopril may be related to an inhibition of angiotensin II formation and/or a direct action of this drug on protein permeability of glomerular basement membrane.
ISSN:1660-8151
DOI:10.1159/000185584